#wetAMD is a form of “late stage” AMD where abnormal blood vessels grow underneath the retina and can leak fluid and blood which may lead to swelling and damage of the macula, causing vision loss. #ophthalmology #retinadisease
Outlook Therapeutics, Inc.
Biotechnology Research
Cranbury, New Jersey 9,540 followers
ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO
Über uns
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
- Website
-
http://www.outlooktherapeutics.com
External link for Outlook Therapeutics, Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Cranbury, New Jersey
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2011
Standorte
-
Primäre
Wegbeschreibung erhalten
7 Clarke Dr
Cranbury, New Jersey 08512, US
Employees at Outlook Therapeutics, Inc.
Aktualisierungen
-
We are working to enhance the standard of care for bevacizumab for retina diseases. Learn more: https://bit.ly/3RkpyHY #ophthalmology #retinadisease #wetAMD
-
-
We are excited for the near-term milestones on the horizon as we drive our NORSE EIGHT program and commercial preparations forward. Full release: https://bit.ly/3X47Jkz #wetAMD #ophthalmology #retinadisease
-
-
Join us for our quarterly conference call and webcast happening today at 8:30 AM ET here: https://bit.ly/4cpmum4 #wetAMD #ophthalmology #retinadisease
-
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update. https://bit.ly/3X47Jkz #wetAMD #ophthalmology #retinadisease
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update | Outlook Therapeutics, Inc...
ir.outlooktherapeutics.com
-
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. https://bit.ly/3SKZBD0 #wetAMD #retinadisease #ophthalmology
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference | Outlook Therapeutics, Inc.
ir.outlooktherapeutics.com
-
Russ Trenary, CEO of Outlook Therapeutics, emphasizes the importance of the stringent FDA and EU quality standards for an ophthalmic solution of bevacizumab. #ophthalmology #retinadisease #wetAMD
-
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast. https://bit.ly/3WUN3ew #wetAMD #ophthalmology #retinadisease
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call a...
ir.outlooktherapeutics.com
-
Outlook Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2024. https://bit.ly/4bZLL6k #ophthalmology #retinadisease #wetAMD
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024 | Outlook Therapeutics, Inc.
ir.outlooktherapeutics.com
-
Receive instant updates on our news, events and filings with email notifications. Sign up today! https://bit.ly/48ZjFXP #ophthalmology #retinadisease #wetAMD
-
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Outlook Therapeutics, Inc.
13 total rounds
![]()
Syntone Ventures
Siehe mehr Informationen auf crunchbase
Letzte Runde
Eigenkapital nach dem IPO
Externer Crunchbase Link für die letzte Finanzierungsrunde
US$ 5.0M
Investoren